Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Anticancer therapeutic strategies for targeting mutant p53-Y220C

9 Oct 2023

Abstract excerpt

The tumor suppressor p53 is a transcription factor with a powerful antitumor activity that is controlled by its negative regulator murine double minute 2 (MDM2, also termed HDM2 in humans) through a feedback mechanism. At the same time, TP53 is the most frequently mutated gene in human cancers. Mutant p53 proteins lose wild-type p53 tumor suppression functions but acquire new oncogenic properties, among which are...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Epigenetics and DNA Methylation
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38738269
DOI: 10.7555/jbr.37.20230093

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Anticancer therapeutic strategies for targeting mutant p53-Y220CPMID 38738269Read ↗

Discovery of Nanomolar-Affinity Pharmacological Chaperones Stabilizing the Oncogenic p53 Mutant Y220CSemantic proximity Read ↗

A Small Molecule Reacts with the p53 Somatic Mutant Y220C to Rescue Wild-type Thermal Stability.Semantic proximity Read ↗

Small molecules that targeting p53 Y220C protein: mechanisms, structures, and clinical advances in anti-tumor therapySemantic proximity Read ↗

Discovery of Rezatapopt (PC14586), a First-in-Class, Small-Molecule Reactivator of p53 Y220C Mutant in DevelopmentSemantic proximity Read ↗

Targeting Cavity-Creating p53 Cancer Mutations with Small-Molecule Stabilizers: the Y220X Paradigm.Semantic proximity Read ↗

Targeting the p53 cancer mutants Y220C, Y220N, and Y220S with the small-molecule stabilizer rezatapopt.Semantic proximity Read ↗

Targeting Oncogenic Mutant p53 for Cancer TherapySemantic proximity Read ↗

Construction of Small-Molecule Deubiquitinase-Targeting Chimeras to Reactivate and Stabilize Mutant p53 Y220C in Vitro and in Vivo.Semantic proximity Read ↗

Small molecule induced reactivation of mutant p53 in cancer cells.Semantic proximity Read ↗

p53: from understanding its structure to advances in therapeutic targeting.Semantic proximity Read ↗

Discovery of Drugs Targeting Mutant p53 and Progress in Nano-Enabled Therapeutic Strategy for p53-Mutated Cancers.Semantic proximity Read ↗

Anticancer Therapeutic Strategies Targeting p53 Aggregation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.